BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20697856)

  • 1. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
    Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
    Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.
    Jeong EG; Kim MS; Nam HK; Min CK; Lee S; Chung YJ; Yoo NJ; Lee SH
    Clin Cancer Res; 2008 Jun; 14(12):3716-21. PubMed ID: 18559588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
    Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
    J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of tofacitinib to achieve an objective response in a
    Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
    Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
    Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
    Elliott NE; Cleveland SM; Grann V; Janik J; Waldmann TA; Davé UP
    Blood; 2011 Oct; 118(14):3911-21. PubMed ID: 21821710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
    Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
    Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
    [No Abstract]   [Full Text] [Related]  

  • 9. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
    Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
    Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
    J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK3
    Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
    Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK1 rs310241 and JAK3 rs3008 Genotypes May Increase Susceptibility to Psoriasis: A Case Control Study.
    Sayed KS; El-Komy MHM; Shehata H; ElShazly SH; El Desouky ED; Amr KS; ElAraby NM; AlOrbani AM
    Skin Pharmacol Physiol; 2020; 33(4):207-212. PubMed ID: 32877908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
    Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
    Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
    Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
    Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
    Batista CR; Lim M; Laramée AS; Abu-Sardanah F; Xu LS; Hossain R; Bell GI; Hess DA; DeKoter RP
    Blood Adv; 2018 Nov; 2(21):2798-2810. PubMed ID: 30355579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.
    Xiang Z; Zhao Y; Mitaksov V; Fremont DH; Kasai Y; Molitoris A; Ries RE; Miner TL; McLellan MD; DiPersio JF; Link DC; Payton JE; Graubert TA; Watson M; Shannon W; Heath SE; Nagarajan R; Mardis ER; Wilson RK; Ley TJ; Tomasson MH
    Blood; 2008 May; 111(9):4809-12. PubMed ID: 18160671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.